X (Twitter) LinkedIn
    Tuesday, November 28
    Login
    0 Shopping Cart
    X (Twitter) LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals & Transactions»Blueberry Therapeutics secures additional GBP3.6m Series B investment
    Deals & Transactions

    Blueberry Therapeutics secures additional GBP3.6m Series B investment

    February 17, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Drug discovery and development company, Blueberry Therapeutics, has secured a GBP3.6 million extension to its previously successful GBP10.8 million Series B fundraising.

    Japanese investor, Medical Incubator Japan (MIJ), and a private syndicate of US Board Certified Dermatologists – led by Dr Omar Ibrahimi of the Connecticut Skin Institute – have invested GBP3.1 million and GBP500k, respectively.

    BB2603 is Blueberry Therapeutics lead drug candidate and is now in Phase II of clinical development. It is designed to enhance the delivery of terbinafine – an anti-fungal medicine – under the nail and to treat infections quickly and effectively, using a smaller dose.

    The additional GBP3.6m funding will support the Phase II dose-finding study, ahead of Phase III clinical development in the US and EU for the treatment of onychomycosis.

    Read more at: Private Equity Wire

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    deals Investments
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Warburg Pincus surpasses target to close $17bn private equity fund

    October 18, 2023

    Brookfield banks $12B for its largest PE fund

    October 18, 2023

    Animal drugs maker Dechra agrees to lower £4.5bn takeover by Swedish private equity firm EQT

    June 3, 2023

    Warburg and Advent in the lead to acquire Baxter’s biopharma unit

    May 13, 2023

    Comments are closed.

    Other Articles

    Revolut worth $33B as European valuations continue to soar

    July 16, 2021

    Royal Caribbean to Sell Azamara Brand to Sycamore Partners

    January 22, 2021

    Angeles Equity Buys Primus Aerospace

    June 14, 2021

    Italy’s Piaggio Aerospace invited five bidders to make purchase offer

    February 27, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    X (Twitter) LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?